Tue, Oct 21, 2014, 12:45 PM EDT - U.S. Markets close in 3 hrs 15 mins

Recent

% | $
Quotes you view appear here for quick access.

LeapFrog Enterprises Inc. Message Board

micocaptraded 7 posts  |  Last Activity: Sep 4, 2014 12:27 PM Member since: Jan 17, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Rights Offering

    by micocaptraded Sep 4, 2014 11:50 AM
    micocaptraded micocaptraded Sep 4, 2014 12:27 PM Flag

    I guess we're talking any time in the next six months and that a material event (e.g., army contract, more on DaVita) could negate the need for the rights offering.

  • micocaptraded by micocaptraded Sep 4, 2014 11:50 AM Flag

    I've not been a participant in a rights offering before. I assume my broker will contact me with the offer to purchase or does it happen some other way. Also, the press release I read did not indicate the date - do we know when it will happen? TIA.

  • If Eva fights we fight too.

    More than a year ago now we were told there were no useful therapeutic options for Eva after her relapse. We were told that as we were regional and would have to travel so far, clinical trials shouldn’t really be considered. Basically, we were told to go home, let the cancer take its course and wait for her to die. Simply not something we were going to do.

    To fight, we eventually turned our view away from standard therapy and began exploring the molecular pathways of her tumour rather than the tumour itself. The very basic theory behind this incredible area of molecular biology is that unveiling gene abnormalities will give insight into characteristics and weaknesses of a tumour. Often different tumour types share the same common characteristics. For example, a brain tumour which showed no response to standard therapy, tested positive for an abnormal BRAF gene which is common in melanoma. The tumour was halted and shrunk after being treated with a standard melanoma drug. This sounds much simpler than it actually is, as pathways can have incredible complexities, but incredibly exciting at the same time. However, the existence of a potential weakness for treatment and the development of drugs to attack that weakness are often at far opposite ends of the field, especially in the world of rare paediatric cancers. This is where money becomes the driving factor for change in the development of drugs for preclinical and clinical trials.

    The results of Eva’s recent genetic profiling report on the tumour from her amputated arm has indicated some interesting findings. It has provided insight into why the cabozantinib is having some effect, and has also provided two other pathways of attack on the tumours. Like the cabozantinib though, there is no paediatric clinical data for use of drugs on these pathways. We expect to fight again.

    Eva continues to do well in everything she puts her little heart to.

  • micocaptraded micocaptraded Aug 29, 2014 12:20 PM Flag

    Yahoo posters always wrong! Yes, indeed, you nitwit.

  • micocaptraded micocaptraded Aug 21, 2014 10:07 PM Flag

    You promised to leave - so why are you back? Nothing like a liar.

  • micocaptraded by micocaptraded Jul 29, 2014 7:52 PM Flag

    see Yahoo Finance lead article. Forecast is also up. Should be good for all relatively decent bio techs and especially a good one like EXEL.

  • Reply to

    Roche

    by saltydog711 Jul 20, 2014 11:59 AM
    micocaptraded micocaptraded Jul 21, 2014 4:07 PM Flag

    Huh? You are not long a stock if you are short!

LF
6.03+0.080(+1.34%)12:44 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.